TrialThe Lancet. Oncology2015

Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.

Jordi Bruix et al.PubMed ↗Publisher ↗

No numbers read from the abstract.